<?xml version="1.0" encoding="UTF-8"?>
<p id="Par56">The mAb market enjoys a healthy pipeline and is expected to grow at an increasing pace, with a current valuation of $115.2 billion in 2018 [
 <xref ref-type="bibr" rid="CR44">44</xref>]. Despite this high growth potential, new companies are unlikely to take over large shares of the market, which is currently dominated by seven companies: Genentech (30.8%), Abbvie (20.0%), Johnson &amp; Johnson (13.6%), Bristol-Myers Squibb (6.5%), Merck Sharp &amp; Dohme (5.6%), Novartis (5.5%), Amgen (4.9%), with other companies comprising the remaining 13% [
 <xref ref-type="bibr" rid="CR44">44</xref>].
</p>
